These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 16904573)
1. Pleiotropic effects of statins and early benefit in the PROVE IT-TIMI-22 study. Poli A; Pujia A J Am Coll Cardiol; 2006 Aug; 48(4):852; author reply 852-3. PubMed ID: 16904573 [No Abstract] [Full Text] [Related]
2. C-reactive protein levels and outcomes after statin therapy. Clearfield M Curr Atheroscler Rep; 2006 Jan; 8(1):8-9. PubMed ID: 16455006 [No Abstract] [Full Text] [Related]
3. Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study. Kashima Y; Izawa A; Aizawa K; Koshikawa M; Kasai H; Tomita T; Kumazaki S; Tsutsui H; Koyama J; Ikeda U J Cardiol; 2009 Aug; 54(1):76-9. PubMed ID: 19632524 [TBL] [Abstract][Full Text] [Related]
4. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Cannon CP; McCabe CH; Belder R; Breen J; Braunwald E Am J Cardiol; 2002 Apr; 89(7):860-1. PubMed ID: 11909576 [No Abstract] [Full Text] [Related]
5. C-reactive protein levels and outcomes after statin therapy. Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E; N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109 [TBL] [Abstract][Full Text] [Related]
6. [First comparison of 2 statins shows: only radical LDL lowering stops coronary atherosclerosis]. Einecke D MMW Fortschr Med; 2003 Dec; 145(51-52):38. PubMed ID: 14974329 [No Abstract] [Full Text] [Related]
7. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Ray KK; Cannon CP Am J Cardiol; 2005 Sep; 96(5A):54F-60F. PubMed ID: 16126024 [TBL] [Abstract][Full Text] [Related]
8. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Wiviott SD; de Lemos JA; Cannon CP; Blazing M; Murphy SA; McCabe CH; Califf R; Braunwald E Circulation; 2006 Mar; 113(11):1406-14. PubMed ID: 16534008 [TBL] [Abstract][Full Text] [Related]
9. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575 [TBL] [Abstract][Full Text] [Related]
10. Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study). Tung P; Wiviott SD; Cannon CP; Murphy SA; McCabe CH; Gibson CM Am J Cardiol; 2009 Apr; 103(8):1056-60. PubMed ID: 19361589 [TBL] [Abstract][Full Text] [Related]
11. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Taylor AJ; Kent SM; Flaherty PJ; Coyle LC; Markwood TT; Vernalis MN Circulation; 2002 Oct; 106(16):2055-60. PubMed ID: 12379573 [TBL] [Abstract][Full Text] [Related]
12. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial. Rouleau J Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805 [TBL] [Abstract][Full Text] [Related]
15. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061 [TBL] [Abstract][Full Text] [Related]
16. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Ray KK; Cannon CP Curr Opin Lipidol; 2004 Dec; 15(6):637-43. PubMed ID: 15529022 [TBL] [Abstract][Full Text] [Related]
17. Seasonal variation in lipids: should we consider it more? Manfredini R; Salmi R; Boari B; Manfredini F Am J Cardiol; 2009 Sep; 104(5):739-40. PubMed ID: 19699358 [No Abstract] [Full Text] [Related]
18. Low-density lipoprotein lowering and atherosclerosis progression: does more mean less? Shah PK Circulation; 2002 Oct; 106(16):2039-40. PubMed ID: 12379568 [No Abstract] [Full Text] [Related]
19. LIFE and ARBITER. Liebson PR Prev Cardiol; 2003; 6(2):108-11. PubMed ID: 12732798 [No Abstract] [Full Text] [Related]
20. Usefulness of lowering low-density lipoprotein cholesterol to <70 mg/dl and usefulness of C-reactive protein in patient selection. Kent SM; Taylor AJ Am J Cardiol; 2003 Nov; 92(10):1224-7. PubMed ID: 14609606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]